Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | CCNK | O75909 | 1/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.34 |
| ▸ | CCR8 | P51685 | 1/20 | 0.33 |
| ▸ | KAT7 | O95251 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1360376 | 0.88 | CYP3A4 (0.39) | CYP3A4 | |
| SCHEMBL1360031 | 0.85 | CYP3A4 (0.37) | CYP3A4CHEK1CCNT1CCNKCCNE1 | |
| SCHEMBL1358412 | 0.85 | CYP3A4 (0.37) | CYP3A4CHEK1CCNT1CCNKCCNE1 | |
| SCHEMBL3144591 | 0.85 | CYP3A4 (0.37) | CYP3A4CHEK1CCNT1CCNKCCNE1 | |
| SCHEMBL1359501 | 0.81 | CYP3A4 (0.37) | CYP3A4CCR8 | |
| SCHEMBL1358014 | 0.81 | CYP3A4 (0.37) | CYP3A4CCR8 | |
| SCHEMBL1359503 | 0.80 | CYP3A4 (0.37) | CYP3A4CCR8 | |
| SCHEMBL1359467 | 0.77 | CYP3A4 (0.39) | CYP3A4 | |
| SCHEMBL1976985 | 0.74 | CYP3A4 (0.34) | CYP3A4 | |
| SCHEMBL1360375 | 0.73 | CYP3A4 (0.39) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067442-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2011-11-29 | — | — | US | disclosed |
| EP-2334662-A1 | PYRINE OR PYRAZINE DERIVATIVES FOR TREATING HCV | F. Hoffmann-La Roche AG (CH) | 2011-06-22 | — | — | EP | disclosed |
| US-20100081658-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC | 2010-04-01 | — | — | US | disclosed |
| WO-2010034671-A1 | PYRINE OR PYRAZINE DERIVATIVES FOR TREATING HCV | F. HOFFMANN-LA ROCHE AG (CH) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081658-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, POLR2A, HCCS | CYP3A4 713/4885CHEK1 1363/4885CCNT1 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.